181 related articles for article (PubMed ID: 20350665)
21. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
22. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
23. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
Zell JA; Yoon EJ; Ignatius Ou SH; Hoefs JC; Chang JC
Anticancer Drugs; 2005 Jan; 16(1):83-5. PubMed ID: 15613909
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
25. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
Kilickap S; Yavuz B; Aksoy S; Sahiner L; Dincer M; Harputluoglu H; Erman M; Aytemir K; Tokgozoglu L; Barista I
Med Oncol; 2008; 25(4):437-42. PubMed ID: 18415035
[TBL] [Abstract][Full Text] [Related]
26. A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma.
Provencio M; Sanchez A; Maximiano C; Cantos B; Méndez M; Bonilla F
Leuk Lymphoma; 2009 Oct; 50(10):1642-6. PubMed ID: 19757315
[TBL] [Abstract][Full Text] [Related]
27. Treatment strategies in elderly patients with aggressive histology lymphoma.
Kouroukis CT; Meyer RM
Ann Hematol; 2001; 80 Suppl 3():B86-8. PubMed ID: 11757717
[No Abstract] [Full Text] [Related]
28. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
[TBL] [Abstract][Full Text] [Related]
29. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.
Lamar ZS; Dothard A; Kennedy L; Isom S; Robinson M; Vaidya R; Hurd D; McClain D; Lesser G
Leuk Lymphoma; 2018 Aug; 59(8):1871-1877. PubMed ID: 29252084
[TBL] [Abstract][Full Text] [Related]
30. Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa.
Zuze T; Ellis GK; Kasonkanji E; Kaimila B; Nyasosela R; Nyirenda R; Tomoka T; Mulenga M; Chikasema M; Tewete B; Mtangwanika A; Chiyoyola S; Chimzimu F; Kampani C; Mhango W; Nicholas S; Randall C; Montgomery ND; Fedoriw G; Westmoreland KD; Painschab MS; Gopal S
Cancer Med; 2020 Jan; 9(1):77-83. PubMed ID: 31705618
[TBL] [Abstract][Full Text] [Related]
31. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
32. Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma.
Aguiar Bujanda D; Aguiar Morales J; Bohn Sarmiento U; Saura Grau S; Rodríguez Franco C
Clin Transl Oncol; 2009 Sep; 11(9):604-8. PubMed ID: 19776000
[TBL] [Abstract][Full Text] [Related]
33. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C
J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242
[TBL] [Abstract][Full Text] [Related]
34. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma.
Wöhrer S; Chott A; Drach J; Püspök A; Hejna M; Hoffmann M; Raderer M
Ann Oncol; 2004 Nov; 15(11):1680-3. PubMed ID: 15520071
[TBL] [Abstract][Full Text] [Related]
36. Rituximab: therapeutic benefit! Vitamin R?
Mo C; Vire B; Wiestner A
Semin Hematol; 2010 Apr; 47(2):105-6. PubMed ID: 20350656
[No Abstract] [Full Text] [Related]
37. Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
Anglin P; Strauss BA; Brandwein JM
Leuk Lymphoma; 1993 Nov; 11(5-6):469-72. PubMed ID: 7510192
[TBL] [Abstract][Full Text] [Related]
38. Aggressive lymphoma: improving treatment outcome with rituximab.
Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
[TBL] [Abstract][Full Text] [Related]
39. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
40. Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin's lymphoma.
Reilly TB; Schuster DM; Starsiak MD; Kost CB; Halkar RK
Clin Nucl Med; 2007 Jul; 32(7):569-71. PubMed ID: 17581351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
